CoChat

Preserving Kidney Function Instead of Replacing It

Open access
Kliger, Alan S., Brosius, Frank C., on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology · 2020 · Clinical Journal of the American Society of Nephrology

The DOI matches its Crossref record, with a small difference in title or year; 4 of the 4 references it cites were found in a registry or an index.

Abstract

For the past 50 years, public and private funding priorities in the field of nephrology focused on kidney replacement therapy for ESKD: dialysis and transplantation. This focus was appropriate in a world where there were very few effective therapies to save lives or halt progressive loss of kidney function for the majority of CKDs. The time has come to change that paradigm as new strategies have emerged to prevent CKD progression and cardiovascular events in patients with CKD and diabetes. Until the latter half of the 20th century, the emerging discipline of nephrology examined the function of normal kidneys, the interaction of the kidneys with other vital organs, the kidneys’ role in multisystem dysfunction, and the physiology and pathophysiology of the many diseases affecting kidney function. In that era, physicians and scientists drawn to nephrology worked hard to preserve kidney function because there was no effective treatment for patients who developed irreversible kidney failure, and death was inevitable. Once it was shown that dialysis could remove uremic toxins and perform as an artificial kidney, attention turned to creating ways to preserve life once the kidneys failed. It was quickly shown that this technology could significantly extend the life of patients with ESKD and, in 1972, Congress passed the Social Security Amendments that provided Medicare coverage for virtually all Americans of any age who had ESKD (1). This public policy was the first and only to underwrite the care of a chronic disease for patients of any age. Currently, Medicare spends $35 billion annually for ESKD care (2). This public funding spawned the large dialysis industry and shaped the way we think about and treat kidney diseases. The prevalence of CKDs in the general population is approximately 15%. More than two thirds of those with CKDs or ESKD also have concurrent diabetes and/or cardiovascular disease (3). A system to classify the severity of CKDs was introduced in 2002. This helped quantify the burden of disease and anticipate ESKD, but a frequent unintended consequence was to focus on disease progression, rather than its underlying cause. In an era when research shed little light on treatments to ameliorate or stop progression of CKD to ESKD, public policy focused on treating kidney failure was appropriate. Although the mortality rate of CKD in diabetes is nearly 20% per year once kidney function begins to decline (4,5), research on ways to prevent CKD or slow its progression lagged behind similar research in other disciplines. Perhaps the wide availability of dialysis and underappreciation of the fatality risk contributed to the dearth of clinical studies. In other fields, where the risk of death and the unavailability of end stage disease treatment were apparent, a combination of activist pressure and federal government action accelerated research efforts that led to the rapid development of effective treatments. Perhaps the best example is the response to HIV/AIDS. During the first years of the AIDS epidemic, federal government responses were lackluster and conflicted. But eventually, largely due to the pressure of activists and a number of congressional supporters, legislation was passed to markedly enhance research into the etiology and treatment of AIDS and to underwrite the delivery of effective treatments to a largely marginalized AIDS population. Critical among these efforts was the expansion of AIDS research funding from <0.1% of the National Institutes of Health (NIH) budget in fiscal year 1982 to 9.8% of the NIH budget in fiscal year 1990 (6). In addition, the Health Resources and Services Administration’s Ryan White HIV/AIDS Program, enacted in 1990, provided “a comprehensive system of HIV primary medical care, essential support services, and medications for low-income people living with HIV who [were] uninsured and underserved. The Program funded grants to states, cities/counties, and local community-based organizations to provide care and treatment services to people living with HIV to improve health outcomes and reduce HIV transmission among hard-to-reach populations” (7). In addition, the Minority AIDS Initiative, passed in 1999 by Congress under the Ryan White Program, provided a new set of appropriations to improve access to HIV care and health outcomes for disproportionately affected minority populations, such as black people. As a result of all of these initiatives, by the end of the 1990s highly active antiretroviral therapy was widely disseminated and the number of new AIDS cases and deaths from HIV/AIDS plummeted. Importantly, federal funding for research, medical care, and community delivery of HIV/AIDS programs has continued now for >20 years. Fortunately, times are also changing for patients living with CKD. Recently published studies have shown clear evidence that new treatments for diabetes can slow or stop CKD progression and, importantly, reduce cardiovascular events, death, and the ne

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2215/cjn.07820719

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Kliger, A. S., Brosius, F. C., & on behalf of the Diabetic Kidney Disease Task Force of the American Society of Nephrology
Affiliations
  • American Society of Nephrology (US)
  • University of Arizona (US)
Corresponding author
Kliger, Alan S.
Venue
Clinical Journal of the American Society of Nephrology
Published
2019-10-08
Volume
15
Issue
1
Pages
129-131
ISSN
  • 1555-9041 (ISSN-L)
  • 1555-905X
OpenAlex
W2979593238
Cited by
20
References
4
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 1
FWCI
2.12
Type
journal article
Language
en
Open access
Locations
  • Clinical Journal of the American Society of Nephrology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK114857)
Topics
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords
chronic kidney disease, end-stage renal disease, renal function preservation, renal replacement therapy, dialysis, kidney transplantation, chronic kidney disease progression, diabetes mellitus, cardiovascular risk, research funding priorities, history of nephrology, CKD risk stratification
MeSH terms
Sodium-Glucose Transporter 2 Inhibitors, Angiotensin-Converting Enzyme Inhibitors, Renal Dialysis, Humans, Kidney, Renin-Angiotensin System, Kidney Transplantation, Treatment Outcome, Recovery of Function, Renal Insufficiency, Chronic, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.